Back to results
US 2016/0355588 A1Published application
Bispecific CD3 and CD19 Antigen Binding Constructs
AssigneeZymeworks Inc.
InventorsGordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter von Kreudenstein
Life of this patent
Estimating the term…
Abstract
Bispecific antigen binding constructs are described that bind to CD3 and CD19 or CD20 antigens.
Claims29
An isolated bispecific antigen binding construct comprising a first antigen-binding polypeptide construct which monovalently and specifically binds a CD19 antigen and is a Fab;
- a second antigen-binding polypeptide construct which monovalently and specifically binds a CD3 antigen and is an scFv;
- and
- a heterodimeric Fc comprising first and second Fc polypeptides each comprising a modified CH3 domain, wherein each modified CH3 domain comprises asymmetric amino acid modifications that promote the formation of a heterodimeric Fc and the dimerized CH3 domains having a melting temperature (Tm) of about 68° C. or higher, wherein the first Fc polypeptide is linked to the first antigen-binding polypeptide construct, with or without a first linker, and the second monomeric Fc polypeptide is linked to the second antigen-binding polypeptide construct with or without a second linker.
(canceled)
-7. (canceled)
-13. (canceled)
-20. (canceled)
-23. (canceled)
(canceled)
-31. (canceled)
(canceled)
-36. (canceled)
Dependencies are inferred from the claim text.